H
Helmut Oettle
Researcher at Humboldt University of Berlin
Publications - 83
Citations - 4123
Helmut Oettle is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Gemcitabine & Pancreatic cancer. The author has an hindex of 29, co-authored 83 publications receiving 3888 citations. Previous affiliations of Helmut Oettle include Hannover Medical School.
Papers
More filters
Journal ArticleDOI
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E. Van Cutsem,H. van de Velde,Petr Karasek,Helmut Oettle,Walter L. Vervenne,A. Szawlowski,Patrick Schöffski,S. Post,Chris Verslype,H. Neumann,Howard Safran,Yves Humblet,J. Perez Ruixo,Y. Ma,D. D. Von Hoff +14 more
TL;DR: In this article, a randomized, double-blind, placebo-controlled study was conducted to determine whether the addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) to standard gemcitabine therapy improves overall survival in advanced pancreatic cancer.
Journal ArticleDOI
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle,Hanno Riess,Jens Stieler,Gerhard Heil,Ingo Schwaner,Jörg Seraphin,Martin Görner,Matthias Mölle,Tim F. Greten,Volker Lakner,Sven Bischoff,Marianne Sinn,Bernd Dörken,Uwe Pelzer +13 more
TL;DR: Second-line OFF significantly extended the duration of overall survival when compared with FF alone in patients with advanced gemcitabine-refractory pancreatic cancer.
Journal ArticleDOI
Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.
Jörg Beyer,N. Schwella,Jürgen Zingsem,I Strohscheer,I Schwaner,Helmut Oettle,S. Serke,Dieter Huhn,W Stieger +8 more
TL;DR: It is concluded that the use of PBPC mobilized by chemotherapy plus G-CSF results in sustained trilineage reconstitution after HDCT, which occurs more rapidly as compared with BM.
Journal ArticleDOI
High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Wolfgang Siegert,Jörg Beyer,Imke Strohscheer,Herrad Baurmann,Helmut Oettle,Jorgen Zingsem,Robert Zimmermann,Carsten Bokemeyer,Hans-Joachim Schmoll,Dieter Huhn +9 more
TL;DR: High-dose carboplatin, etoposide, and ifosfamide plus autologous stem-cell transplantation can be used in refractory and relapsed germ cell cancer with acceptable toxicity, and represents an effective, potentially curative salvage treatment.
Journal ArticleDOI
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Marianne Sinn,Marcus Bahra,Torsten Liersch,Klaus Gellert,Helmut Messmann,Wolf O. Bechstein,Dirk Waldschmidt,Lutz Jacobasch,Martin Wilhelm,Bettina Rau,Robert Grützmann,Arndt Weinmann,Georg Maschmeyer,Uwe Pelzer,Jens Stieler,Jana K. Striefler,Michael Ghadimi,Sven Bischoff,Bernd Dörken,Helmut Oettle,Hanno Riess +20 more
TL;DR: The CONKO-005 study is the first study to investigate the combination of chemotherapy and a targeted therapy in the adjuvant treatment of PDAC and found that adding erlotinib to gemcitabine did not improve DFS or overall survival over Gem.